In order to understand the molecular mechanisms that could help explain the therapeutic role of venetoclax, we focused on BCL2-related genes and the JAK/STAT pathway that could collectively contribute to venetoclax long-lasting response in BM and EM. The gene discussed is BCL2; the disease is erythema multiforme.